[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"coagulation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:coagulation":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,41,76,96,117,140,161,189],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":16,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":25,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100627367","reference-range-study-for-the-quantra-system-with-the-qplus-cartridge-in-pediatric-patients-100627367",false,"NCT07447713","Reference Range Study for the Quantra System With the QPlus Cartridge in Pediatric Patients","Inclusion Criteria:\n\n* Subject is \\\u003C18 years of age\n* Corrected gestational age ≥ 37weeks\n* Subject is scheduled for an elective surgery, non-surgical intervention or diagnostic procedure requiring anesthesia and vascular access with an ASA score ≤3.\n* Subject's parent or guardian has signed an informed consent form. If required, subject has signed an assent form.\n\nExclusion Criteria:\n\n* Subject is hospitalized in the Pediatric Intensive Care Unit\n* Subject requires Extracorporeal Membrane Oxygenation (ECMO)\n* Subject has had an infection within 7 days of the scheduled procedure\n* Subject has an active coagulation disorder (bleeding or thrombosis)\n* For subjects that have a hemoglobin measurement within 24 hours of the scheduled procedure, hemoglobin is \\\u003C8g\u002FdL or \\>16g\u002FdL\n* Subject has a baseline oxygen saturation \\\u003C92%","ALL","17 Years",{"count":18,"type":19},240,"ESTIMATED","OBSERVATIONAL","This study will determine reference range intervals for the parameters reported by the Quantra System with the QPlus Cartridge in pediatric patients.",[23,24],"Pediatric","Coagulation",[26,27],"Reference range","Quantra QPlus","NOT_YET_RECRUITING","2026-02-26",{"date":31,"type":32},"2026-03-03","ACTUAL",{"date":34,"type":19},"2026-04-15",{"date":36,"type":19},"2027-05-30",{"name":38,"class":39},"HemoSonics LLC","INDUSTRY",4,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":15,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":60,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":75},"100594075","contact-activation-of-coagulation-in-newly-inserted-central-venous-catheters-100594075","NCT07014722","Contact Activation of Coagulation in Newly Inserted Central Venous Catheters","Contact Activation of Coagulation in Newly Inserted Central Catheters - a Randomized Controlled Trial","CAS-2","Inclusion Criteria\n\nParticipants must meet all of the following criteria to be included in the study:\n\n1. Clinical indication for the placement of a two-lumen central venous catheter with length 150-160 mm.\n2. Age ≥18 years.\n3. Signed informed consent.\n\nExclusion Criteria\n\nParticipants meeting any of the following criteria will be excluded:\n\n1. Current use of anticoagulants or platelet inhibitors, except: Prophylactic low molecular weight heparin (LMWH), double prophylactic dose of LMWH, Acetylsalicylic acid (ASA).\n2. Prothrombin complex (pK\u002FINR) outside the normal range (0.9-1.2), platelet count \\\u003C50 × 10⁹\u002FL or haemoglobin \\\u003C 80 g\u002FL, if already available.\n3. Known coagulopathic conditions, including but not limited to:\n\n   * Activated protein C (APC) resistance,\n   * Hemophilia A or B,\n   * Vitamin K deficiency,\n   * Disseminated intravascular coagulation (DIC),\n   * Antiphospholipid syndrome,\n   * von Willebrand disease, Other known congenital or acquired bleeding disorders.","18 Years",{"count":51,"type":19},88,"INTERVENTIONAL",[54],"NA","A central venous catheter (CVC) is a thin plastic tube placed into one of the body's large veins, typically in the neck or near the clavicle. CVCs are crucial for administering medications, fluids, and secure blood samples. Although CVCs are an essential tool in healthcare, there are certain risks and complications associated with their use. CVCs can affect the body's coagulation system, potentially leading to the formation of blood clots at the site of the catheter. This can result in serious complications, and in some cases, increased morbidity and mortality. Despite the known risk of blood clot formation with catheter use, it is still do not fully understand why clots occur or how a newly inserted catheter affects the coagulation system.\n\nThe aim of this randomized controlled trial is to compare four different central venous catheters and their impact on the coagulation system.\n\nEighty eight patients ≥18 years of age, who require a CVC and agree to participate in the study will be randomly assigned to one of the four predetermined, commonly used, central venous catheters. Two blood samples will be taken from the newly inserted catheter. The first blood sample (Sample 1) will be collected within seconds after catheter insertion without pre-flushing the catheter with saline. The second blood sample (Sample 2) will be taken after the catheter has been flushed with at least 10 ml saline and the initial blood discarded. All samples will be taken from the distale lumen without any connectors. Samples 1 and 2 will then be analyzed to measure how the coagulation system is affected after contact with the inside surface of the CVC. The blood samples will also be compared between the different catheter types and in overall cohort irrespective of group .\n\nThe study could provide valuable information on how the coagulation system is affected after catheter insertion. This knowledge could help improve preventive measures to reduce the risk of blood clot formation and ensure safer blood sampling for patients with venous catheters.",[57,24,58,59],"Central Venous Catheter","Coagulation Activation","Central Venous Catheter Complications",[61,62,63],"coagulation","ROTEM","central venous catheter","RECRUITING","2026-02-13",{"date":67,"type":32},"2026-02-18",{"date":69,"type":32},"2025-09-10",{"date":71,"type":19},"2026-12-30",{"name":73,"class":74},"Thomas Kander","OTHER",1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":75},"100385524","evaluation-of-pro-inflammatory-leukocyte-activity-in-patients-undergoing-cardiac-surgery-100385524","NCT04299828","Evaluation of Pro-Inflammatory Leukocyte Activity in Patients Undergoing Cardiac Surgery","Inclusion Criteria:\n\n* Patients (all ages) undergoing complex cardiac surgical procedures with CPB.\n\nExclusion Criteria:\n\n* undergoing an emergent procedure and do not have more than 1 hour ahead of time to review the consent\n* patient in a moribund condition American Society of Anesthesiology (ASA 5) -patient with a hematological and\u002For oncological disease\n* Jehovah witnesses.",{"count":83,"type":19},100,"The goal of this proposal is to prospectively collect data from a series of 200 patients (all ages) undergoing complex cardiac surgical procedures involving cardiopulmonary bypass (CPB) to:\n\n1. Measure the number of blood activated circulating monocytes before, during and after cardiac surgery and serum GABA and pro-inflammatory cytokine levels\n2. Understand the correlation between GABA and inflammatory cytokines (and\u002For activated monocytes) and\n3. Assess the correlation between thrombosis and monocyte activation in patients undergoing cardiac surgery under CPB and at risk of thrombosis.",[86,24],"Congenital Heart Disease","2026-01-05",{"date":89,"type":32},"2026-01-07",{"date":91,"type":32},"2022-05-31",{"date":93,"type":19},"2026-12",{"name":95,"class":74},"Boston Children's Hospital",{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":15,"minAge":49,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":40},"100593888","clinical-performance-evaluation-of-native-whole-blood-samples-of-patients-on-doacs-with-the-perosphere-clotchek-100593888","NCT07012291","Clinical Performance Evaluation of Native Whole Blood Samples of Patients on DOACs With the Perosphere ClotChek™","Multi-site Clinical Performance Evaluation of Native Whole Blood Samples of Patients on Direct Oral Anticoagulants (DOACs) With the Perosphere ClotChek™ Coagulometer","Inclusion Criteria:\n\n* Be informed of the nature of the study and provide written informed consent before any study-specific procedures are performed.\n* Be 18- to 80-years-of-age, inclusive, at time of consent.\n* Have suitable venous access for at least a single venipuncture.\n* Eligible patients on anticoagulants must have taken their prescribed anticoagulant regularly at least for one month prior to study participation for inclusion\n* Eligible patients on anticoagulants must have been on their anticoagulant therapy for at least one month.\n\nExclusion Criteria:\n\n* Have a personal or family history of clotting disorder or hematologic abnormality, such as excessive bleeding, joint hematoma, thrombovascular disease, thrombocytopenia, or any chronic condition requiring treatment with transfusions, other than the condition for which a DOAC was prescribed.\n* Have a history of unexplained syncope.\n* Have a history within six months prior to Screening of peptic ulcer or gastrointestinal bleeding (including hematemesis, melena, or rectal bleeding).\n* Consume more than five cigarettes per day.\n* If female, have a history of excessive or dysfunctional uterine bleeding (unless the subject had a subsequent hysterectomy).\n* If female, be pregnant, breastfeeding, or planning to become pregnant during the study.","80 Years",{"count":105,"type":19},150,"The Perosphere ClotChek™ system consists of a hand-held, battery-operated blood coagulation instrument and disposable test cuvettes for use at the point-of-care (POC). The instrument performs a whole blood clotting time (WBCT) test using freshly drawn, non-citrated whole blood. The purpose of the present study is to characterize the performance of the Perosphere ClotChek™ as a quantitative measurement of the WBCT in patients taking one of the following Direct Oral Anticoagulants (DOACs), rivaroxaban or apixaban.",[24],"2025-09-09",{"date":110,"type":32},"2025-09-16",{"date":112,"type":32},"2025-06-20",{"date":114,"type":19},"2027-06-01",{"name":116,"class":39},"Perosphere Technologies Inc.",{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":15,"minAge":49,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":125,"conditions":126,"keywords":129,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":75},"100391477","thrombo-embolic-events-in-hospitalized-patients-with-covid-19-serious-acute-pneumopathy-100391477","NCT04377490","Thrombo Embolic Events in Hospitalized Patients With Covid-19 Serious Acute Pneumopathy","THROMBCOVID2","Inclusion Criteria:\n\n* all patients hospitalized in Amiens Hospital with COVID-19 infection\n\nExclusion Criteria:\n\n* patients\\\u003C 18 years",{"count":83,"type":19},"The understanding of haemostasis and inflammation cross-talk has gained considerable knowledge during the past decade in the field of arterial and venous thrombosis. Complex and delicately balanced interaction between coagulation and inflammation involve all cellular and humoral components.\n\nElements of the coagulation system such as activated thrombin, fibrinogen or factor Xa may increase inflammation by promoting the production of proinflammatory cytokines, chemokines, growth factors and adhesion molecules that lead to a procoagulant state amplifying the pathological process. Recent evidence supports inflammation as a common pathogenic contributor to both arterial and venous thrombosis, giving rise to the concept of inflammation induced thrombosis.\n\nPatients with infection of COVID-19 and severe pneumoniae seem to have higher risk of thromboembolism. The purpose of this project is to analyze hemostasis and coagulation of every hospitalized patient with infection of COVID-19.\n\nBlood sample for coagulation and hemostasis analysis will be collected on every patient hospitalized in Amiens hospital for COVID-19 infection. Thrombin time, factors V and II, fibrin\u002Ffibrinogen degradation products, antithrombin will be assessed every week. Anticardiolipin, anti-beta2 glycoprotein I and anti-annexin A2 antibodies IgG and IgM at day of admission and at fourth week after admission will be assessed. SARS-CoV2 viral load and serodiagnosis will be performed at the same time. At the same time venous ultrasound to diagnose thrombosis will be performed.",[127,128,24],"COVID-19","Hemostasis",[127,130,128,61],"venous ultrasound","2025-05-23",{"date":133,"type":32},"2025-05-29",{"date":135,"type":32},"2020-05-04",{"date":137,"type":19},"2025-11",{"name":139,"class":74},"Centre Hospitalier Universitaire, Amiens",{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":15,"minAge":49,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":149,"conditions":150,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":75},"100505769","role-of-coagulation-inflammation-and-vessels-in-chronic-liver-disease-100505769","NCT05865691","Role of Coagulation, Inflammation and Vessels in Chronic Liver Disease","CLUE","Inclusion Criteria:\n\nPatients with chronic liver disease:\n\nPatients over 18 years of age Patients affiliated with a social security plan or entitled to receive benefits Patients with chronic liver disease or cirrhosis whose diagnosis is based on one or more of the following\n\n* Liver biopsy showing chronic liver disease or cirrhosis\n* Liver elastography by Fibroscan® assessing the elasticity of the liver at more than 10 kpa\n* Combination of clinical, biological and imaging criteria characteristic of chronic liver disease (signs of portal hypertension, liver failure and liver dysmorphia in a patient with at least one risk factor for chronic liver disease)\n\nControls without liver disease Patients 18 years of age with no known liver disease Patients who have had blood drawn in the hospital prior to surgery (pre-operative work-up as part of the care process).\n\nExclusion Criteria:\n\nCommon non-inclusion criteria for patients with chronic liver disease and controls without liver disease will be as follows:\n\n* Pregnant or lactating women\n* Protected populations: persons under guardianship, under curatorship or safeguard of justice\n* Patient under AME\n* Patient who has not signed a consent form\n* Recent surgery before the blood test (\\\u003C 2 weeks)\n* Transfusion of blood products (packed red blood cells, platelet concentrates, fresh frozen plasma, etc.) recently (\\\u003C 2 weeks)\n* Use of medication that interferes with hemostasis\n* Active extra-hepatic cancer or cancer less than 5 years old\n* Organ transplantation (liver, kidney, lung, heart)",{"count":148,"type":19},360,"Chronic liver diseases represent a major public health problem and are responsible for more than 150,000 deaths in Europe each year. These diseases are accompanied by symptoms that profoundly alter the quality of life and mainly affect people of working age, leading to a major economic impact.\n\nCoagulation disorders, inflammation and vascular alterations are associated with chronic liver diseases but their role in the onset and\u002For progression of liver diseases is still not fully understood.\n\nA better understanding of chronic liver diseases and in particular of the factors that play a role in the onset and progression of these diseases would improve patient management and therefore have a positive impact on individuals, but also on the healthcare system and the economy.",[151,24],"Chronic Liver Diseases","2024-07-31",{"date":154,"type":32},"2024-08-01",{"date":156,"type":32},"2023-09-07",{"date":158,"type":19},"2035-12-31",{"name":160,"class":74},"Assistance Publique - Hôpitaux de Paris",{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":15,"minAge":168,"maxAge":4,"enrollmentInfo":169,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":170,"conditions":171,"keywords":176,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":75},"100555555","cellular-immunity-neuroendocrine-and-inflammatory-factors-for-clinical-prognosis-in-acute-coronary-syndrome-100555555","NCT06513611","Cellular Immunity, Neuroendocrine, and Inflammatory Factors for Clinical Prognosis in Acute Coronary Syndrome","Identificación de la relación Entre Componentes de la Inmunidad Celular y Factores Inflamatorios y neuroendócrinos Como Determinantes Del pronóstico clínico en el síndrome Coronario Agudo","Inclusion Criteria:\n\n* Are over 21 years of age and admitted to the Coronary Unit of the Hospital de Clínicas with a diagnosis of Acute Coronary Syndrome (ACS).\n* Agree to participate in the study through informed consent.\n\nExclusion Criteria:\n\n* Concomitant diagnosis of chronic neoplastic or inflammatory disease.\n* Diagnosis of allergic disease, parasitic disease, asthma, or hypereosinophilic syndrome.\n* Severe associated valvular disease.\n* Acute myocardial infarction (AMI) in the previous month.\n* Chronic corticosteroid treatment.\n* Creatinine clearance \\\u003C30% by MDRD (Modification of Diet in Renal Disease).\n* Severe hepatic insufficiency.\n* Pregnant women.\n* Known disease that limits their life expectancy to 6 months.\n* Refuse to participate in the study either by their own will or unable to understand its characteristics due to their clinical condition.","21 Years",{"count":105,"type":19},"In acute coronary syndrome (ACS), there is an increase in cortisol levels, as an expression of the stress response, and C-reactive protein, as an expression of the inflammatory response, which are in turn associated with changes in the components of cellular immunity, and ultimately are predictors of clinical events. The objective of this study is to demonstrate that, within the frame of reference of ACS, beyond the thrombotic phenomenon that leads to ischemia and myocardial necrosis, there is an activation of an inflammatory and stress response, evidenced by an elevation of CRP and cortisol, respectively, and sequentially modifications in the components of cellular immunity in peripheral blood that convey prognostic value during hospitalization and after discharge. A prospective, observational, analytical, unicentric study of consecutive patients with ACS, with telephone follow-up to 6 months, will be carried out. For 2 years, all eligible patients admitted with a diagnosis of ACS to the Coronary Care Unit of the Hospital de Clínicas José de San Martín in Buenos Aires will be registered consecutively.",[172,173,174,175,24],"Acute Coronary Syndrome","Stress Hyperglycemia","Cortisol; Hypersecretion","Inflammatory Response",[177,178,179],"acute coronary syndrome","inflammation","cellular immunity","2024-07-16",{"date":182,"type":32},"2024-07-22",{"date":184,"type":32},"2024-01-01",{"date":186,"type":19},"2026-07-01",{"name":188,"class":74},"Hospital de Clinicas José de San Martín",{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":195,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":15,"minAge":49,"maxAge":197,"enrollmentInfo":198,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":200,"conditions":201,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":217},"100504858","observational-dutch-young-symptomatic-stroke-study---next-100504858","NCT05853796","Observational Dutch Young Symptomatic StrokE studY - nEXT","Observational Dutch Young Symptomatic StrokE studY - Extended","ODYSSEY-nEXT","Inclusion Criteria:\n\n* Patients with a first-ever transient ischemic attack (TIA) or acute ischemic stroke aged between 18 and 50 years old\n* For this study, acute stroke is defined as \"occurence of acute neurological deficit lasting more than 24 hours, with confirmation on imaging (CT(-a) or MR(-a))\".TIA is defined as \"occurence of acute neurological deficit lasting less than 24 hours with confirmation of ischemia on MRI).\n* Patients have a kidney function eGFR\\>30ml\u002Fmin.\n\nExclusion Criteria:\n\n* A history of clinical TIA, ischemic stroke or intracerebral hemorrhage\n* A intracerebral hemorrhage resulting from trauma, known aneurysm or underlying intracerebral malignancy.\n* A venous infarction, retinal infarction or amourosis fugax.\n* Inadequate control of the Dutch language to reliably sign an informed consent from and\u002For participate in the follow-up\n* Patients are excluded if they have a contra indication for 3T MRI.","50 Years",{"count":199,"type":19},280,"BACKGROUND: Worldwide, 2 million patients aged 18-50 years suffer an ischemic stroke each year with an increasing trend over the past decade due to yet unknown reasons. Whereas prognosis and antithrombotic treatment in older patients with cardiovascular disease are among the best studied topics in clinical medicine, this does not hold true for patients at young age. It is of great importance to treat these patient groups correctly to prevent recurrence and bleeding complications. However, previous research have shown that there is a long-term increased risk of recurrent ischemic events despite the secondary prevention and a subsequent increased bleeding risk. To tailor effective antithrombotic therapy to the individual patient, it is essential to understand the underlying pathogenesis and identify modifiable risk factors in young patients for recurrence or bleeding. It is thought that abnormalities of hemostasis may play a key role in early-onset ischemic stroke. First, prothrombotic conditions are associated with an increased risk for ischemic stroke at young age. In addition, disturbance of the hemostatic balance due to one or several triggers can activate the coagulation cascade, which on its turn can lead or contribute to clot formation and subsequent arterial occlusion. In previous study, there were indications that trigger factors such as fever and\u002For an infection in the days prior to the stroke may play a role in the pathogenesis. This suggests that an interaction between inflammation, endothelial damage and coagulation may lead to the formation of a clot. In this observational study we aim to investigate the role of the immune system, endothelial damage and coagulation in the pathogenesis and prognosis of stroke in young patients.\n\nOBJECTIVE: To investigate the role of hemostasis, inflammation and endothelial activation in the etiology and prognosis in an acute ischemic stroke (or TIA) in young stroke patients.\n\nSTUDY DESIGN: Multicentre prospective observational study\n\nSTUDY POPULATION:\n\nAll patients aged between 18 and 50 years old with a first-ever ischemic stroke or TIA who are admitted to the neurology ward or seen at the outpatient clinic of one of the participating centers.\n\nMain exclusion criteria are: history of clinical TIA, ischemic stroke or intracerebral hemorrhage. A intracerebral hemorrhage resulting from trauma, known aneurysm or underlying intracerebral malignancy. A venous infarction, retinal infarction and amourosis fugax. Inadequate control of the Dutch language to reliably sign an informed consent from and\u002For participate in the follow-up. Patients are excluded if they have a contra indication for 3T MRI.\n\nIn addition 60 healthy controls (18-50 years old) will be included.\n\nMAIN STUDY ENDPOINTS:\n\n1. Baseline and 3 months coagulation profile:\n\n   Whole blood and platelet poor plasma thrombin generation, platelet function tests, and coagulation biomarkers, screening for thrombophilia.\n2. Baseline and 3 months inflammation\u002Fendothelial activation profile:\n\n   Cytokines\u002Fchemokines, expression of receptors\u002Fcofactors related to hemostasis on peripheral blood mononuclear cells (PBMCs), stimulation tests of PBMC's to assess trained immunity.\n3. Vessel wall enhancement on 3 Tesla MRI\n4. Questionnaire trigger factors",[202,203,204,205,206,207,24],"Ischemic Stroke","Stroke in the Young","Cardiovascular Diseases","Cerebrovascular Disorders","Embolism and Thrombosis","Thrombophilia","2023-05-02",{"date":210,"type":32},"2023-05-11",{"date":212,"type":32},"2023-02-06",{"date":214,"type":19},"2037-01-01",{"name":216,"class":74},"Radboud University Medical Center",6]